Skip to main content

Pipeline And Milestones

Platform Candidate Program Area
Pre-Clinical
Phase 1
Phase 2
Phase 3
 Status Partner Next Milestone
Gene-Based Therapy
 Recurrent Glioblastoma
Phase 2
Randomized Controlled Study
Status: Recruiting
UCLA Memorial Sloan Kettering Cancer Center Dana Farber Cancer Institute UT Health San Antonio
 Recruiting Nano-Carrier (Japan) Wholly-owned ROW Preliminary Data - 2022
Colorectal Cancer
Phase 2
Nivolumab Combo
Status: Recruiting
National Cancer Institute
 Recruiting Preliminary Data - 2022
Monocyte Targeting Technology (MTT)
Monoclonal Antibodies
 VB-601 Anti-inflammatory
Phase 1
Status: IND Enabling Studies
 IND Enabling Studies Wholly-owned First in Human – 4Q22